Literature DB >> 19937823

Recent advances in physicochemical and ADMET profiling in drug discovery.

Jianling Wang1, Suzanne Skolnik.   

Abstract

The drastic increase in the cost for discovering and developing a new drug along with the high attrition rate of development candidates led to shifting drug-discovery strategy to parallel assessment of comprehensive drug physicochemical, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties alongside efficacy. With the proposal of a profiling paradigm and utilization of integrated risk assessment, one can exponentially enhance the predictive power of in vitro tools by taking into consideration the interplay among profiling parameters. In particular, this article will review recent advances in accurate assessment of solubility and other physicochemical parameters. The proper interpretation of these experimental data is crucial for rapid and meaningful risk assessment and rational optimization of drug candidates in drug discovery. The impact of these tools on assisting drug-discovery teams in establishing in vitro-in vivo correlation (IVIVC) as well as structure-property relationship (SPR) will be presented.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19937823     DOI: 10.1002/cbdv.200900117

Source DB:  PubMed          Journal:  Chem Biodivers        ISSN: 1612-1872            Impact factor:   2.408


  9 in total

Review 1.  Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system.

Authors:  Jaewon Lee; Dong-Gyu Jo; Daeui Park; Hae Young Chung; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

2.  Quantitative Retention (Structure)-Activity Relationships in Predicting the Pharmaceutical and Toxic Properties of Potential Pesticides.

Authors:  Małgorzata Janicka; Anna Śliwińska
Journal:  Molecules       Date:  2022-06-03       Impact factor: 4.927

3.  Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells.

Authors:  Su Mi Choi; Yonghak Kim; Joong Sup Shim; Joon Tae Park; Rui-Hong Wang; Steven D Leach; Jun O Liu; Chuxia Deng; Zhaohui Ye; Yoon-Young Jang
Journal:  Hepatology       Date:  2013-06       Impact factor: 17.425

4.  Integrated Isogenic Human Induced Pluripotent Stem Cell-Based Liver and Heart Microphysiological Systems Predict Unsafe Drug-Drug Interaction.

Authors:  Felipe T Lee-Montiel; Alexander Laemmle; Verena Charwat; Laure Dumont; Caleb S Lee; Nathaniel Huebsch; Hideaki Okochi; Matthew J Hancock; Brian Siemons; Steven C Boggess; Ishan Goswami; Evan W Miller; Holger Willenbring; Kevin E Healy
Journal:  Front Pharmacol       Date:  2021-05-07       Impact factor: 5.810

5.  Prediction of In-silico ADME Properties of 1,2-O-Isopropylidene Aldohexose Derivatives.

Authors:  Strahinja Z Kovačević; Lidija R Jevrić; Sanja O Podunavac Kuzmanović; Eva S Lončar
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

Review 6.  Current status and future directions of high-throughput ADME screening in drug discovery.

Authors:  Wilson Z Shou
Journal:  J Pharm Anal       Date:  2020-05-23

7.  Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2.

Authors:  Hualou Liang; Liang Zhao; Xiajing Gong; Meng Hu; Hongbin Wang
Journal:  Clin Transl Sci       Date:  2021-05-02       Impact factor: 4.689

8.  Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.

Authors:  Shilpi Khare; Advait S Nagle; Agnes Biggart; Yin H Lai; Fang Liang; Lauren C Davis; S Whitney Barnes; Casey J N Mathison; Elmarie Myburgh; Mu-Yun Gao; J Robert Gillespie; Xianzhong Liu; Jocelyn L Tan; Monique Stinson; Ianne C Rivera; Jaime Ballard; Vince Yeh; Todd Groessl; Glenn Federe; Hazel X Y Koh; John D Venable; Badry Bursulaya; Michael Shapiro; Pranab K Mishra; Glen Spraggon; Ansgar Brock; Jeremy C Mottram; Frederick S Buckner; Srinivasa P S Rao; Ben G Wen; John R Walker; Tove Tuntland; Valentina Molteni; Richard J Glynne; Frantisek Supek
Journal:  Nature       Date:  2016-08-08       Impact factor: 49.962

9.  Multiparameter Optimization of Trypanocidal Cruzain Inhibitors With In Vivo Activity and Favorable Pharmacokinetics.

Authors:  Ivani Pauli; Celso de O Rezende; Brian W Slafer; Marco A Dessoy; Mariana L de Souza; Leonardo L G Ferreira; Abraham L M Adjanohun; Rafaela S Ferreira; Luma G Magalhães; Renata Krogh; Simone Michelan-Duarte; Ricardo Vaz Del Pintor; Fernando B R da Silva; Fabio C Cruz; Luiz C Dias; Adriano D Andricopulo
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.